CannabisNewsBreaks – University of British Columbia to Conduct Clinical Study of Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Game-Changing Oral CBD Product
While cannabidiol and other marijuana-derived substances are traditionally smoked, this can cause damage to the lungs, and edible cannabis products have their drawbacks, too—typically being filled with sugars or other sweeteners to mask the unpleasant flavor associated with cannabis compounds. With its pioneering TurboCBD™ product, however, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral CBD intake, having engineered the product to enhance absorption through the intestinal tract without active compounds being destroyed by stomach acid or broken down by the liver, and this revolutionary product also masks the unpleasant flavor of cannabis compounds. An article further discussing this…
